Critically ill corona patients will probably soon be able to receive an existing anti-inflammatory drug.
A low dose of that agent, dexamethasone, can increase the chance that they survive the infection.
The regulator for the medication in Europe, the European Medicines Agency in Amsterdam, therefore supports the use of the drug.
Dexamethasone is intended for corona patients who are receiving supplemental oxygen or are entirely on a ventilator. They should get six milligrams a day for ten days.
Dexamethasone can prevent one death for every eight ventilated patients, Oxford University reported in June following a trial involving more than 6,000 participants.
In patients receiving oxygen support, dexamethasone could prevent 1 death in every 25 patients.